Suppr超能文献

利用脂肪组织衍生治疗剂实现移植耐受。

Toward transplantation tolerance with adipose tissue-derived therapeutics.

机构信息

Center for Vascularized Composite Allotransplantation, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.

Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.

出版信息

Front Immunol. 2023 Apr 28;14:1111813. doi: 10.3389/fimmu.2023.1111813. eCollection 2023.

Abstract

Solid organ and composite tissue allotransplanation have been widely applied to treat end-stage organ failure and massive tissue defects, respectively. Currently there are a lot of research endeavors focusing on induction of transplantation tolerance, to relieve the burden derived from long-term immunosuppressant uptake. The mesenchymal stromal cells (MSCs) have been demonstrated with potent immunomodulatory capacities and applied as promising cellular therapeutics to promote allograft survival and induce tolerance. As a rich source of adult MSCs, adipose tissue provides additional advantages of easy accessibility and good safety profile. In recent years, the stromal vascular fraction (SVF) isolated from adipose tissues following enzymatic or mechanical processing without culture and expansion has demonstrated immunomodulatory and proangiogenic properties. Furthermore, the secretome of AD-MSCs has been utilized in transplantation field as a potential "cell-free" therapeutics. This article reviews recent studies that employ these adipose-derived therapeutics, including AD-MSCs, SVF, and secretome, in various aspects of organ and tissue allotransplantation. Most reports validate their efficacies in prolonging allograft survival. Specifically, the SVF and secretome have performed well for graft preservation and pretreatment, potentially through their proangiogenic and antioxidative capacities. In contrast, AD-MSCs were suitable for peri-transplantation immunosuppression. The proper combination of AD-MSCs, lymphodepletion and conventional immunosuppressants could consistently induce donor-specific tolerance to vascularized composite allotransplants (VCA). For each type of transplantation, optimizing the choice of therapeutics, timing, dose, and frequency of administration may be required. Future progress in the application of adipose-derived therapeutics to induce transplantation tolerance will be further benefited by continued research into their mechanisms of action and the development of standardized protocols for isolation methodologies, cell culture, and efficacy evaluation.

摘要

实体器官和复合组织同种异体移植已广泛应用于治疗终末期器官衰竭和大量组织缺损。目前有许多研究致力于诱导移植耐受,以减轻长期服用免疫抑制剂带来的负担。间充质基质细胞(MSCs)具有强大的免疫调节能力,并被应用于促进同种异体移植物存活和诱导耐受的有前途的细胞治疗。脂肪组织是 MSC 的丰富来源,具有易于获取和良好的安全性的额外优势。近年来,通过酶或机械处理而无需培养和扩增从脂肪组织中分离的基质血管部分(SVF)已显示出免疫调节和促血管生成特性。此外,AD-MSCs 的分泌组已被用于移植领域作为一种潜在的“无细胞”治疗方法。本文综述了最近使用这些脂肪来源的治疗剂(包括 AD-MSCs、SVF 和分泌组)在器官和组织同种异体移植各个方面的研究。大多数报告证实了它们延长移植物存活的功效。具体而言,SVF 和分泌组在保存和预处理移植物方面表现良好,这可能是通过其促血管生成和抗氧化能力。相比之下,AD-MSCs 适合于移植前免疫抑制。AD-MSCs、淋巴细胞耗竭和常规免疫抑制剂的适当组合可以持续诱导血管化复合同种异体移植(VCA)的供体特异性耐受。对于每种类型的移植,可能需要优化治疗剂的选择、时间、剂量和给药频率。通过对其作用机制的持续研究以及分离方法、细胞培养和功效评估标准化方案的开发,脂肪来源的治疗剂在诱导移植耐受方面的应用将取得进一步进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/653f/10175575/a9919f524c1a/fimmu-14-1111813-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验